Trial Profile
A Randomised Comparison of Daily 25 mg Versus 5 mg Lenalidomide as Maintenance Therapy After High-Dose Therapy and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Aug 2020
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms LenaMain
- 17 Aug 2020 Results assessing efficacy and tolerability of high versus low dose lenalidomide maintenance therapy of multiple myeloma after autologous blood stem cell transplantation published in the Clinical Cancer Research
- 04 Dec 2018 Results assessing the Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology